NCT06138028
Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Jul 2024); last known: Recruiting
- Notable Primary endpoints revised (2)
- Secondary endpoints revised (2)
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Overall survival (OS)
Timeframe: up to 24 months
Progression-free survival (PFS)
Timeframe: up to 12 months
Secondary (2)
overall response rate (ORR)
toxicities
Arms and interventions
Combined chemo-immuno-irradiationExperimental
TP regimen plus PD-1 inhibitor for 4 cycles then irradiation and PD-1 inhibitor maintenance therapy for 13 cycles.
Drugs: TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors(Sintilimab)
Sites
2 sites in 1 country